KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Non-cash Items (2011 - 2012)

Bristol Myers Squibb (BMY) reported Non-cash Items of $394.0 million for Q4 2012, down 44.03% year-over-year from $704.0 million in Q1 2012, and down 44.03% on a QoQ basis from $704.0 million in Q4 2011.

Bristol Myers Squibb (BMY) has 2 years of Non-cash Items data on file, last reported at $394.0 million in Q4 2012.

  • Quarterly Non-cash Items fell 44.03% year-over-year to $394.0 million in Q4 2012, while the trailing twelve-month figure through Dec 2012 was $394.0 million (down 44.03% YoY) and the FY2012 annual result came in at $394.0 million, down 44.03% from the prior year.
  • Non-cash Items eased to $394.0 million in Q4 2012 per BMY's latest filing, from $704.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $704.0 million in Q4 2011 and bottomed at $394.0 million in Q4 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2012 394.00 Mn
Dec 31, 2012 394.00 Mn
Dec 31, 2011 704.00 Mn
Dec 31, 2011 704.00 Mn